ClinicalTrials.gg
CompletedNCT03225352Updated Jun 6, 2018

A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets

A Phase 1 interventional study of 500 mg acetylsalicylic acid (Aspirin, BAYE4465) and 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) in Moderate Pain, sponsored by Bayer. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
78th of 86
12 · median 100
Started
2017
with 7 others
Phase 1
9 of 86
none open now
Registered
58th of 86
by date
Lead sponsor
2 of 86
Bayer

Among the 86 studies testing ibuprofen in Pain, this one is the 78th largest by enrollment, is one of 8 that started in 2017, is one of 9 in phase 1, and was the 58th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets

03

Conditions studied

  • Moderate Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers aged 18 to 65 years included
  • Verified diagnosis of "healthy"
  • Non-smokers or passive smokers
  • in the range of 18.5 to 30 kg/m2
  • Subject has given written to participate in the trial prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  • Blood donation within the last 90 days prior to planned randomization
  • Any previous medication within 10 days before the planned administration of the radiolabelled Medicinal Product (rIMP) which, in the opinion of the physician responsible, will interfere with the study procedures or compromise safety
  • Subject has any non-removable metal objects such as metal plates, screws etc. in their chest or abdominal area which, in the opinion of the physician responsible, could affect the study conduct.
  • Vegetarian
  • Subjects for whom participation in this study will exceed the limits of total radiation exposure allowed in any 12 month period (5 Millisievert), or will exceed 10 Millisievert over any three year period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Sequence 1: starting with BAYE4465 500 mg

    Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design

    Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 400 mg ibuprofen(Nurofen) · Drug: 400 mg ibuprofen (Dolormin Extra)

  • Experimental
    Sequence 2: starting with BAYE4465 1000 mg

    Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design

    Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 400 mg ibuprofen(Nurofen) · Drug: 400 mg ibuprofen (Dolormin Extra)

  • Experimental
    Sequence 3: starting with Nurofen

    Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design

    Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 400 mg ibuprofen(Nurofen) · Drug: 400 mg ibuprofen (Dolormin Extra)

  • Experimental
    Sequence 4: starting with Dolormin Extra

    Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design

    Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465) · Drug: 400 mg ibuprofen(Nurofen) · Drug: 400 mg ibuprofen (Dolormin Extra)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to complete tablet disintegration

    The tablet is radiolabeled. Scintigraphy images of the abdominal area will be taken It is time until an image with no definable hot spot remaining is identified

    Time frame: Up to 4 hours

Secondary outcomes

  1. Gastric empty time, if applicable

    Gastric emptying time will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  2. Time of colon arrival, if applicable

    Time of colon arrival will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  3. Small intestine transit time, if applicable

    Small intestine transit time will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  4. Time of onset of release of radiolabel

    Time of onset of release of radiolabel will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  5. Site of onset of release of radiolabel

    Site of onset of release of radiolabel will be determined by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  6. Site of completion of release of radiolabel

    Site of completion of release of radiolabel will be determined by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  7. Disintegration rate of the tablet estimated from the radioactivity remaining

    Disintegration rate of the tablet estimated from the radioactivity rem will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  8. Time of 50% disintegration of the tablet estimated from the radioactivity remaining

    Time of 50% disintegration of the tablet estimated from the radioactivity remaining will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  9. Gastric emptying kinetics of dispersed radioactive material (t50% and t90%)

    Gastric emptying kinetics of dispersed radioactive material (t50% and t90%) will be calculated by a qualified assessor based on the scintigraphy images

    Time frame: Up to 4 hours

  10. AUC0-t

    Area under the plasma concentration vs time curve from zero to the last data point

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

  11. Cmax

    Maximum drug concentration in plasma after single dose administration

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

  12. AUC0-infinity

    Area under the plasma concentration vs time curve from zero to infinity

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

  13. t1/2

    Half-life associated with the terminal slope

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

  14. tmax

    Time to reach maximum drug concentration in the measured

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

  15. Cmax/AUC0-infinity

    Time frame: Prior to dosing (between 60-15 min), and 5, 9, 13, 18, 23, 28, 33, 38, 48, 58, 68, 78, 88, 118, 178 and 238 min post-dose

07

Study locations

1 site
  • Bio-Images Research Ltd
    Glasgow, Glasgow City G4 0SF, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Oct 2017, 2 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 2 months is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2017
First posted
Jul 21, 2017
StartActual
Aug 7, 2017
Primary completionActual
Oct 7, 2017
CompletionActual
Oct 16, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03225352
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Aug 7, 2017
Primary completion
Oct 7, 2017
Completion
Oct 16, 2017
Last update
Jun 6, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Ibuprofen

Start the discussion